MOLECULAR PARTNERS ADS/1 (6ML0) - Total Liabilities
Based on the latest financial reports, MOLECULAR PARTNERS ADS/1 (6ML0) has total liabilities worth €21.77 Million EUR (≈ $25.45 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 6ML0 cash generation efficiency to assess how effectively this company generates cash.
MOLECULAR PARTNERS ADS/1 - Total Liabilities Trend (2021–2025)
This chart illustrates how MOLECULAR PARTNERS ADS/1's total liabilities have evolved over time, based on quarterly financial data. Check 6ML0 financial resilience to evaluate the company's liquid asset resilience ratio.
MOLECULAR PARTNERS ADS/1 Competitors by Total Liabilities
The table below lists competitors of MOLECULAR PARTNERS ADS/1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MKH Bhd
KLSE:6114
|
Malaysia | RM1.23 Billion |
|
Unicycive Therapeutics Inc
NASDAQ:UNCY
|
USA | $13.13 Million |
|
Midas Minerals Ltd
AU:MM1
|
Australia | AU$287.49K |
|
Hitejinro Holdings
KO:000140
|
Korea | ₩2.87 Trillion |
|
B’IN Live Co Ltd
TW:6625
|
Taiwan | NT$1.73 Billion |
|
Blaize Holdings, Inc.
NASDAQ:BZAI
|
USA | $59.60 Million |
|
UBM Development AG
VI:UBS
|
Austria | €815.52 Million |
|
Sungei Bagan Rubber Malaya
KLSE:2569
|
Malaysia | RM17.53 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down MOLECULAR PARTNERS ADS/1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 6ML0 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MOLECULAR PARTNERS ADS/1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MOLECULAR PARTNERS ADS/1 (2021–2025)
The table below shows the annual total liabilities of MOLECULAR PARTNERS ADS/1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €21.77 Million ≈ $25.45 Million |
+28.90% |
| 2024-12-31 | €16.89 Million ≈ $19.75 Million |
-22.95% |
| 2023-12-31 | €21.92 Million ≈ $25.63 Million |
-19.08% |
| 2022-12-31 | €27.09 Million ≈ $31.67 Million |
-58.56% |
| 2021-12-31 | €65.38 Million ≈ $76.43 Million |
-- |
About MOLECULAR PARTNERS ADS/1
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more